STING Activators as Therapy for Cancer

STING 激活剂治疗癌症

基本信息

  • 批准号:
    10709468
  • 负责人:
  • 金额:
    $ 99.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-17 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The Immuno-oncology (IO) arena affords a new and exciting approach to stimulate the body’s own immune system to fight cancer. The generation of anti-cancer T cells is predominantly triggered by phagocytosed cancer cells stimulating innate immune signaling pathways in professional antigen presenting cells (APC’s). This signaling process is largely governed by STING (stimulator of interferon genes), a cellular protein discovered by the laboratory of Dr. Glen N. Barber that plays an essential role in host defense against infectious disease and cancer. Activation of STING triggers cytokine production and facilitates tumor antigen cross-presentation. Indeed, considerable effort is now underway in the biotech arena to discover techniques to augment STING activity with the objective of invigorating the generation of anti-tumor cytotoxic T cells. Along with check-point inhibitors and CAR-T cell therapy, the plausible utilization of STING agonists affords a new, complementary immunotherapeutic strategy to treat malignant disease. Here, STINGINN, LLC (“STINGINN”), in collaboration with the University of Miami, proposes to perform an FDA approved investigator sponsored small Phase I clinical trial for patients suffering from highly aggressive leukemias, specifically relapsed/refractory acute myeloid leukemia (AML) and adult lymphocytic leukemia (ALL) focusing on HTLV-1 associated adult T cell lymphocytic leukemia (ATLL). Our strategy involves reinfusing autologous tumor cells loaded with STING-dependent adjuvants (STAVs) into patients to stimulate APCs in vivo and thus anti-tumor CTL’s. Our pre-clinical data indicates that STAV loaded cells are highly immunogenic, potent activators of APC’s. We have already submitted an IND FDA application based on this work and have assembled an appropriate team to carry out the proposed trial. Our proposal is also applicable to a variety of cancers, not just leukemia, providing the opportunity to initiate a number of alternate cancer therapeutic trials in the future.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEONGHYUN AHN其他文献

JEONGHYUN AHN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEONGHYUN AHN', 18)}}的其他基金

Human specific STING agonists for the treatment of cancer
用于治疗癌症的人类特异性 STING 激动剂
  • 批准号:
    10759593
  • 财政年份:
    2023
  • 资助金额:
    $ 99.39万
  • 项目类别:
STING Activators as Therapy for Cancer
STING 激活剂治疗癌症
  • 批准号:
    10480641
  • 财政年份:
    2020
  • 资助金额:
    $ 99.39万
  • 项目类别:

相似海外基金

ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
  • 批准号:
    6641447
  • 财政年份:
    2002
  • 资助金额:
    $ 99.39万
  • 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
  • 批准号:
    6468895
  • 财政年份:
    2001
  • 资助金额:
    $ 99.39万
  • 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
  • 批准号:
    6334989
  • 财政年份:
    2000
  • 资助金额:
    $ 99.39万
  • 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
  • 批准号:
    6103535
  • 财政年份:
    1999
  • 资助金额:
    $ 99.39万
  • 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
  • 批准号:
    6269935
  • 财政年份:
    1998
  • 资助金额:
    $ 99.39万
  • 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
  • 批准号:
    5207623
  • 财政年份:
  • 资助金额:
    $ 99.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了